Novocure Partners With Verastem Oncology on Pancreatic Cancer Trial
Bitget2026/10/28 11:02- Novocure entered a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate a combination treatment for locally advanced pancreatic cancer.
- The trial will combine Tumor Treating Fields therapy with chemotherapy and VS-7375, Verastem's investigational oral KRAS G12D inhibitor.
- Enrollment is expected to begin in 2027, targeting approximately 25 patients.
- Researchers will assess safety and tolerability, with preliminary efficacy evaluated as exploratory endpoints.
- Under the agreement, Novocure will manage and fund trial operations; Verastem will supply VS-7375.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
PIEVERSE surged, up 7.91% in 24 hours
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
Crypto prices
More
